Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Hui Lin, Frank Geurts, Luise Hassler, Daniel Batlle, Katrina M. Mirabito Colafella, Kate M. Denton, Jia L. Zhuo, Xiao C. Li, Nirupama Ramkumar, Masahiro Koizumi, Taiji Matsusaka, Akira Nishiyama, Martin J. Hoogduijn, Ewout J. Hoorn, A.H. Jan Danser
Abstract
receptors often being claimed to exert a crucial role. Urinary RAS component levels, depending on filtration, reabsorption, and local release, are believed to reflect renal RAS activity. Finally, both existing drugs (RAS inhibitors, cyclooxygenase inhibitors) and novel drugs (angiotensin receptor/neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, soluble ACE2) affect renal angiotensin formation, thereby displaying cardiovascular efficacy. Particular in the case of the latter three, an important question is to what degree they induce renoprotection (e.g., in a renal RAS-dependent manner). This review provides a unifying view, explaining not only how kidney angiotensin formation occurs and how it is affected by drugs but also why drugs are renoprotective when altering the renal RAS. SIGNIFICANCE STATEMENT: Angiotensin formation in the kidney is widely accepted but little understood, and multiple, often contrasting concepts have been put forward over the last two decades. This paper offers a unifying view, simultaneously explaining how existing and novel drugs exert renoprotection by interfering with kidney angiotensin formation.